2.53
+0.06(+2.43%)
Currency In USD
Address
3500 Lenox Road NE
Atlanta, GA 30326
United States of America
Phone
844 722 6333
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
June 15, 2021
| Name | Title | Pay | Year Born |
| Mr. Stephan Jackman | Chief Executive Officer & Director | 443,617 | 1977 |
| Mr. Milton Charles Ault III | Founder & Vice Chairman | 8,333 | 1970 |
| Mr. Henry C. W. Nisser Esq. | Executive Vice President, General Counsel & Director | 50,000 | 1969 |
| Mr. David J. Katzoff | Chief Financial Officer | 150,000 | 1963 |
| Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance | 0 | 1961 |
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.